Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

The Minister of Public Health Dr. Firass Abiad at COP28 in UAE

 
The Minister of Public Health (MoPH), Dr. Firass Abiad, will be participating in the COP28 held in UAE from November 30 to December 12, where leaders from around the world convene annually to address the dangerous human interference with the climate system. The Minister’s participation in COP28 UAE is particularly important as it would be the first COP with an explicit health focus. Dr. Abiad, the Minister of Public Health, Eng. Joyce Haddad, the Director of Preventive Healthcare at MoPH, Dr. Myriam Mrad, the Director of the Public Health Department at the University of Balamand and the Ministry Technical Collaborator will be representing the ministry of public health in the Lebanese national delegation.  

Minister Abiad will emphasize the imperative need to prioritize public health concerns in Lebanon within the broader discourse on climate change. Acknowledging the undeniable impact of environmental factors on human health, Dr. Abiad will commit to advocate for proactive measures and collaborative strategies to mitigate these effects in Lebanon.

The Minister will stress key initiatives aiming at safeguarding public health amidst environmental shifts, emphasizing the urgency of adaptation measures and the development of resilient healthcare systems. These initiatives align with the Lebanese Ministry of Public Health's commitment to promoting sustainable health practices and ensuring equitable access to healthcare for all citizens.

Additionally, Dr. Abiad will participate in high-level dialogues, fostering collaborations with global stakeholders and reaffirming Lebanon's dedication to the global fight against climate change, particularly in preserving public health.

It is worth noting that earlier this year, the MoPH endorsed COP26 proceedings in an official letter signed and dated March 26, 2023.  As part of this initiative, Lebanon committed to prioritizing the health needs of its population, while simultaneously addressing the environmental and sustainability challenges facing its healthcare facilities.

The MoPH remains steadfast in its commitment to integrating climate resilience into public health policies, aligning efforts with international agendas to safeguard the well-being of citizens and future generations.
    2
ATC Name B/G Ingredients Dosage Form Price
J01MA12 OXALEV G Levofloxacin - 500mg 500mg Tablet, film coated 791,523 L.L
A08AB01 ONLEFIT G Orlistat - 120mg 120mg Capsule 1,537,356 L.L
J01MA12 OXALEV G Levofloxacin - 500mg 500mg Tablet, film coated 565,758 L.L
A08AB01 ORLISTAT-SIGMA G Orlistat - 120mg 120mg Capsule 847,965 L.L
A08AB01 ORLY SLIM G Orlistat - 120mg 120mg Capsule 1,174,518 L.L
S01AA13 OPTIFUCIN VISCOUS G Fusidic acid - 1% 1% Drops 208,296 L.L
A11CC05 ONE BIG-D 10.000 G Vitamin D3 - 10,000IU 10,000IU Capsule 895,895 L.L
A11CC05 OSTEODYN VITAMINE D3 G Vitamin D3 - 100000IU/2ml 100000IU/2ml Solution 618,168 L.L
S01AE01 OPTIFLOX G Ofloxacin - 3mg/ml 3mg/ml Drops suspension 143,791 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 10mg 10mg Tablet, film coated 526,786 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 20mg 20mg Tablet, film coated 667,890 L.L
A11CC05 ORAVIL G Vitamin D3 - 100,000IU/2ml 100,000IU Solution 618,168 L.L
C09CA08 OLMENOR G Olmesartan medoxomil - 40mg 40mg Tablet, film coated 721,643 L.L
S01BA07 OPTILONE G Fluorometholone - 0.1% 0.1% Solution 309,084 L.L
N05AH03 OLANZAMED G Olanzapine - 5mg 5mg Tablet 665,522 L.L
N05AH03 OLANZAPINE ARROW G Olanzapine - 5mg 5mg Tablet 670,577 L.L
S01CA01 OPTIDEX T G Dexamethasone - 1mg/ml, Tobramycin - 3mg/ml Drops suspension 266,081 L.L
N05AH03 OLANZAX 5 G Olanzapine - 5mg 5mg Tablet, mouth dissolving 1,316,966 L.L
N05AH03 OLIZAX 5 G Olanzapine - 5mg 5mg Tablet, mouth dissolving 1,466,580 L.L
M02AA15 OLFEN G Diclofenac sodium (diethylamine) - 1% 1% Gel 268,769 L.L
N05AH03 OLANZAMED G Olanzapine - 20mg 20mg Tablet 3,941,938 L.L
N05AH03 OLANZAX 10 G Olanzapine - 10mg 10mg Tablet, mouth dissolving 2,329,327 L.L
N05AH03 OLIZAX 10 G Olanzapine - 10mg 10mg Tablet, mouth dissolving 2,598,096 L.L
C10BA05 OTOREZA G Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 908,438 L.L
C10BA05 OTOREZA 10/10 G Atorvastatin - 10mg, Ezetimibe - 10mg Tablet, film coated 454,219 L.L
C10BA05 OTOREZA 10MG/20MG G Atorvastatin - 20mg, Ezetimibe - 10mg Tablet, film coated 858,715 L.L
N05AH03 OLANZAMED G Olanzapine - 10mg 10mg Tablet 902,294 L.L
N05AH03 OLANZAPINE ARROW G Olanzapine - 10mg 10mg Tablet 822,432 L.L
C10BA05 OTOREZA 10MG/40MG G Atorvastatin - 40mg, Ezetimibe - 10mg Tablet, film coated 1,144,954 L.L
N05AH03 OLANZAPINE ARROW G Olanzapine - 7.5mg 7.5mg Tablet 822,432 L.L
    2
Sitemap
© Copyrights reserved to Ministry of Public Health 2025